214910-41-5

Basic information

• Product Name: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,ethylester,(1R,3S,4S)-(9CI)
• Synonyms: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,ethylester,(1R,3S,4S)-(9CI);(1R,3S,4S)-2-Azabicyclo[2.2.1]heptane-3-carboxylic acid ethyl ester;(1R,3S,4S)-ETHYL 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLATE
• CAS NO: 214910-41-5
• Molecular Formula: C₉H₁₅NO₂
• Molecular Weight: 169.22
• Product Categories: PYRROLE
• Mol File: 214910-41-5.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,ethylester,(1R,3S,4S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,ethylester,(1R,3S,4S)-(9CI)(214910-41-5)
• EPA Substance Registry System: 2-Azabicyclo[2.2.1]heptane-3-carboxylicacid,ethylester,(1R,3S,4S)-(9CI)(214910-41-5)

Safety Data

• Hazardous Substances Data: 214910-41-5(Hazardous Substances Data)

Usage

Molecular weight

169.22 g/mol
Commonly used in pharmaceuticals and medicinal chemistry
Building block for synthesizing biologically active molecules
Potential applications in chemical biology and drug development
Stereochemistry indicated by (1R,3S,4S) designation
Versatile chemical entity with promising prospects in scientific research and development

Upstream product

• 134984-63-7 (1S,3S,4R)-2-((R)-1-phenyl-ethyl)-2-aza-bicyclo[2.2.1]hept-5-ene-3-carboxylic acid ethyl ester 
• 764622-98-2 (1S,3S,4R)-2-Aza-bicyclo[2.2.1]hept-5-ene-3-carboxylic acid ethyl ester 
• 192461-70-4 ethyl (1R,3S,4S)-2-<(R)-1-phenylethyl>-2-azabicyclo<2.2.1>heptane-3-exo-carboxylate 
• 542-92-7 cyclopenta-1,3-diene 

Downstream Products

• 521970-34-3 (1R,3S,4S)-2-(2-Nitro-benzoyl)-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid ethyl ester 
• 641629-89-2 (1R,3S,4S)-2-Phenylmethanesulfonyl-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid ethyl ester 
• 171754-02-2 (1S,3S,4R)-2-azabicyclo<2.2.1>heptane-3-carboxylic acid 
• 1419391-32-4 C₂₀H₂₇BrN₄O₄ 
• 1419391-22-2 C₂₂H₂₇BrN₂O₆ 
• 1256383-55-7 methyl ((S)-1-((1R,3S,4S)-3-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1256383-56-8 methyl ((S)-3-methyl-1-oxo-1-((1R,3S,4S)-3-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-2-azabicyclo[2.2.1]heptan-2-yl)butan-2-yl)carbamate 
• 1612854-76-8 C₂₁H₂₇BrN₄O₅ 
• 188057-44-5 (1R,3S,4S)-3-formyl-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1588405-36-0 C₂₀H₂₇BrN₄O₄ 
• 1560641-58-8 C₂₂H₂₇BrN₄O₃ 
• 1560641-55-5 C₂₂H₂₇BrN₂O₆ 

Relevant articles and documents

Substituted phenoxy-2-azabicyclo[3.2.1]octane compound as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a substituted phenoxy-2-azabicyclo[3.2.1]octane compound as well as a preparation method and application thereof.The general structural formula I of the substituted phenoxy-2-azabicyclo[3.2.1]octane compound is specifically shown in the specification, wherein R is methyl, methoxy, cyano, fluorine, chlorine, bromine or nitro groups. Pharmacological research shows that the compound shows a good effect in an in-vitro antitumor activity test, and can be used for preparing antitumor drugs. The preparation methodof the substituted phenoxy-2-azabicyclo [3.2.1]octane compound provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.